Clinical trial: Short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia - A randomized, double-blind, placebo-controlled study

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 8, 2010, Pages 834-845

  Gines P ^a   Wong, F ^b   Watson, H ^c   Terg, R ^d   Bruha, R ^e   Zarski, J P ^f   Dudley, F ^g  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b TORONTO GENERAL HOSPITAL   (Canada)

^c SANOFI   (France)

^d HOSPITAL DE GASTROENTEROLOGÍA DR CARLOS BONORINO UDAONDO   (Argentina)

^e CHARLES UNIVERSITY   (Czech Republic)

^f GRENOBLE UNIVERSITY HOSPITAL   (France)

^g ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FUROSEMIDE; PLACEBO; SATAVAPTAN; SODIUM; SPIRONOLACTONE;

ADULT; ARTICLE; ASCITES; BACTERIAL PERITONITIS; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG WITHDRAWAL; ELECTROLYTE BLOOD LEVEL; FEMALE; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERNATREMIA; HYPONATREMIA; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SODIUM BLOOD LEVEL; THIRST; TREATMENT DURATION; VISUAL ANALOG SCALE; WEIGHT REDUCTION;

AGED; ASCITES; BODY WEIGHT; DIURETICS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; FUROSEMIDE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MORPHOLINES; PROSPECTIVE STUDIES; RECEPTORS, VASOPRESSIN; SPIRO COMPOUNDS; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 77949669242     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04236.x     Document Type: Article

References (18)

1. Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Intern 2006 69 : 2124 2130.
2. Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. The Lancet 2008 371 : 1624 1632.
3. Gerbes AL, Gulberg V, Ginès P, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003 124 : 933 939.
4. Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003 37 : 182 191.
5. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective V2-vasopressin receptor antagonist, for hyponatremia. N Engl J Med 2006 355 : 2099 2112.
6. Gheorghiade M, Konstam MS, Burnett JC Jr., et al. Short-term clinical effects of tolvaptan, a vasopressin receptor antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trial. JAMA 2007 297 : 1332 1343.
7. Ginès P, Wong F, Watson H, et al. Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium concentration in cirrhosis with hyponatremia. A randomized trial. Hepatology 2008 48 : 204 213.
8. Ghali JK, Koren MJ, Taylor JR, et al. Efficacy and safety of oral conivaptan: a V1a/V2 vasopressin receptor antagonist assessed in randomized, placebo-controlled trial in patients with euvolemic and hypervolemic hyponatremia. J Clin Endocrinol Metab 2006 91 : 2145 2152.
9. Moore K, Wong F, Ginès P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003 38 : 258 266.
10. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. New Engl J Med 1996 334 : 693 699.
11. Ferenci P, Lockwood K, Mullen K, et al. Hepatic encephalopathy - definition, nomen-clature, diagnosis and quantification: final report of the working party at the 11th world congresses of gastroenterology, Vienna, 1998. Hepatology 2002 35 : 716 721.
12. Turpault S, Duvauchelle T, Santoni A. Tolerability, pharmacokinetics and pharmacodynamics of the selective vasopressin V2 receptor antagonist, satavaptan: a multiple-dose, placebo-controlled study in healthy male subjects. Can J Clin Pharmacol 2008 15 : 710.
13. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new predictive equation. Ann Intern Med 1999 130 : 461 470.
14. Angeli P, Gatta A. Medical treatment of ascites in cirrhosis. In : Ginès P, Arroyo V, Rodés J, Schrier RW, eds. Ascites and Renal Dysfunction in Liver Disease. Pathogenesis, Diagnosis and Treatment. Blackwell Publishing, Malden, MA, 2005 : 227 240.
15. Rozansky DJ. The role of aldosterone in renal sodium transport. Semin Nephrol 2002 26 : 173 181.
16. Bertuccio CA, Ibarra FR, Toledo JE, Arrisurieta EE, Martin RS. Endogenous vasopressin regulates Na-K-.ATPase and Na-K-Cl cotransporter rbsc-1 in rat outer medulla. Am J Physiol Renal Physiol 2002 282 : F265 70.
17. Sterns RH, Riggs JE, Schochet SS Jr. Osmotic demyelination syndrome following correction of hyponatremia. N Engl J Med 1986 314 : 1535 1542.
18. Sterns RH, Silver SM. Brain volume regulation in response to hypo-osmolality and its correction. Am J Med 2006 119 (Suppl 1 S12 6.